Genentech and Curis' vismodegib is submitted for FDA OK

09/12/2011 | Xconomy

Roche Holding unit Genentech is seeking FDA approval of vismodegib, a skin cancer drug developed with Curis. Clinical data show that vismodegib significantly reduces tumors in patients with basal cell carcinoma. The oral treatment works by disrupting the hedgehog biological pathway.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA